MPS Ltd Reports Record Financial Performance in FY26

EBITDA stands at INR 236 crore with a 38.2% ROCE for the fiscal year.
The company recorded a 16.3% growth in Profit After Tax (PAT) and an EPS of INR 102.11.

Reader Takeaway: Strong operational growth driven by Research and Education segments, tempered by the absence of a final dividend.

What just happened

MPS Ltd held its 56th Annual General Meeting (AGM) on September 4, 2026, via video conferencing. The company confirmed that FY26 was its most profitable year to date. Shareholders reviewed the adoption of financial statements, the appointment of new non-executive directors, and the five-year re-appointment of M/s. Walker Chandiok & Co LLP as statutory auditors.

Why this matters

Record financial metrics, including a 30.7% EBITDA margin and a record EPS of INR 102.11, signal strong operational health. The decision to skip a final dividend highlights a shift in capital allocation strategy, prioritizing the integration of recent acquisitions like Unbound Medicine and pursuing new investment opportunities over immediate cash distribution.

Capital Allocation

Management emphasized that the decision to retain earnings is aligned with the company’s long-term growth strategy. Despite the zero-dividend stance for FY26, the company noted a history of returning over INR 650 crore to shareholders across the previous eight years, signaling that the current pause is a strategic choice for growth rather than a long-term policy change.

Risks to watch

Investors should monitor the integration success of Unbound Medicine, as capital deployment into acquisitions carries inherent execution risks. The lack of a final dividend may also impact short-term sentiment among income-focused retail shareholders.

What to track next

The company is expected to release the formal Scrutinizer’s report and the consolidated e-voting results within two working days of the AGM, confirming the final approval status of the proposed board and auditor resolutions.